Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: A practical approach

Human Pathology

Volumn 43, Issue 8, 2012, Pages 1157-1168

  Legolvan, Mark P ^a   Taliano, Ross J ^a   Resnick, Murray B ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Carcinoma; Chromosomal instability; Colon; EGFR; Immunohistochemistry; Lynch syndrome; Microsatellite instability; Molecular; PCR

Indexed keywords

APC PROTEIN; B RAF KINASE; BETA CATENIN; JANUS KINASE; K RAS PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SMAD4 PROTEIN; VASCULOTROPIN;

ADENOMATOUS POLYP; ANEUPLOIDY; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 17; CHROMOSOME 5Q; COLORECTAL CARCINOMA; CPG ISLAND; CYTOGENETICS; DNA METHYLATION; FRAMESHIFT MUTATION; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE;

CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CPG ISLANDS; DNA METHYLATION; HUMANS; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863982455     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.03.003     Document Type: Article

References (110)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
3. S. Ogino, and A. Goel Molecular classification and correlates in colorectal cancer J Mol Diagn 10 2008 13 27 (Pubitemid 351184831)
4. W.M. Grady, and J.M. Carethers Genomic and epigenetic instability in colorectal cancer pathogenesis Gastroenterology 135 2008 1079 1099
5. E.R. Fearon Molecular genetics of colorectal cancer Annu Rev Pathol 6 2011 479 507
6. M. Malumbres, and M. Barbacid RAS oncogenes: the first 30 years Nat Rev Cancer 3 2003 459 465 (Pubitemid 37328850)
7. J.A. McCubrey, L.S. Steelman, and C.R. Kempf Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways J Cell Physiol 226 2011 2762 2781
8. M. Miyaki, and T. Kuroki Role of Smad4 (DPC4) inactivation in human cancer Biochem Biophys Res Commun 306 2003 799 804 (Pubitemid 36776201)
9. K.H. Vousden, and C. Prives Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
10. S.J. Baker, A.C. Preisinger, and J.M. Jessup p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis Cancer Res 50 1990 7717 7722
11. A. Walther, R. Houlston, and I. Tomlinson Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis Gut 57 2008 941 950 (Pubitemid 351919529)
12. E.R. Fearon, K.R. Cho, and J.M. Nigro Identification of a chromosome 18q gene that is altered in colorectal cancers Science 247 1990 49 56
13. S. Popat, and R.S. Houlston A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis Eur J Cancer 41 2005 2060 2070 (Pubitemid 41337947)
14. S. Thiagalingam, C. Lengauer, and F.S. Leach Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers Nat Genet 13 1996 343 346 (Pubitemid 26230501)
15. S. Ogino, K. Nosho, and N. Irahara Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers J Clin Oncol 27 2009 4591 4598
16. C.C. Pritchard, and W.M. Grady Colorectal cancer molecular biology moves into clinical practice Gut 60 2011 116 129
17. S.N. Thibodeau, G. Bren, and D. Schaid Microsatellite instability in cancer of the proximal colon Science 260 1993 816 819 (Pubitemid 23167612)
18. S. Markowitz, J. Wang, and L. Myeroff Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability Science 268 1995 1336 1338
19. B. Jung, R.T. Doctolero, and A. Tajima Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers Gastroenterology 126 2004 654 659 (Pubitemid 38298312)
20. B. Jung, E.J. Smith, and R.T. Doctolero Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers Int J Cancer 118 2006 2509 2513
21. T.A. Kunkel, and D.A. Erie DNA mismatch repair Annu Rev Biochem 74 2005 681 710 (Pubitemid 40995521)
22. J. Jiricny The multifaceted mismatch-repair system Nat Rev Mol Cell Biol 7 2006 335 346
23. J. Shia Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry J Mol Diagn 10 2008 293 300 (Pubitemid 352019113)
24. C.R. Boland, S.N. Thibodeau, and S.R. Hamilton A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 1998 5248 5257 (Pubitemid 28521189)
25. N. Suraweera, A. Duval, and M. Reperant Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR Gastroenterology 123 2002 1804 1811 (Pubitemid 35408304)
26. J.W. Bacher, L.A. Flanagan, and R.L. Smalley Development of a fluorescent multiplex assay for detection of MSI-high tumors Dis Markers 20 2004 237 250 (Pubitemid 40164096)
27. K.M. Murphy, S. Zhang, and T. Geiger Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers J Mol Diagn 8 2006 305 311 (Pubitemid 44063806)
28. L. Zhang Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing J Mol Diagn 10 2008 301 307 (Pubitemid 352019114)
29. S. Popat, R. Hubner, and R.S. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 2005 609 618 (Pubitemid 46224239)
30. C. Guastadisegni, M. Colafranceschi, and L. Ottini Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data Eur J Cancer 46 2010 2788 2798
31. D.B. Longley, U. McDermott, and P.G. Johnston Clinical significance of prognostic and predictive markers in colorectal cancer Pharmacogenomics J 2 2002 209 216 (Pubitemid 35023580)
32. M.L. Chen, C.H. Fang, and L.S. Liang A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/ leucovorin in treating advanced colorectal cancer Surg Oncol 19 2010 38 45
33. C.M. Ribic, D.J. Sargent, and M.J. Moore Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 2003 247 257 (Pubitemid 36859476)
34. G.P. Kim, L.H. Colangelo, and H.S. Wieand Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J Clin Oncol 25 2007 767 772 (Pubitemid 350002875)
35. P.L. Barratt, M.T. Seymour, and S.P. Stenning DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study Lancet 360 2002 1381 1391 (Pubitemid 35341303)
36. K. Bracht, A.M. Nicholls, and Y. Liu 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency Br J Cancer 103 2010 340 346
37. E. Pani, L. Stojic, and M. El-Shemerly Mismatch repair status and the response of human cells to cisplatin Cell Cycle 6 2007 1796 1802 (Pubitemid 47327934)
38. R.P. Topping, J.C. Wilkinson, and K.D. Scarpinato Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling J Biol Chem 284 2009 14029 14039
39. M. Lüchtenborg, M.P. Weijenberg, and P.A. Wark Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study BMC Cancer 5 2005 160
40. M. Toyota, N. Ahuja, and M. Ohe-Toyota CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci USA 96 1999 8681 8686 (Pubitemid 29354851)
41. D.J. Weisenberger, K.D. Siegmund, and M. Campan CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat Genet 38 2006 787 793 (Pubitemid 43980599)
42. W.S. Samowitz, H. Albertsen, and J. Herrick Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer Gastroenterology 129 2005 837 845 (Pubitemid 41242676)
43. S. Ogino, T. Kawasaki, and G.J. Kirkner Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample J Mol Diagn 9 2007 305 314 (Pubitemid 47305066)
44. G.H. Kang Four molecular subtypes of colorectal cancer and their precursor lesions Arch Pathol Lab Med 135 2011 698 703
45. A. Kaneda, and K. Yagi Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes Cancer Sci 102 2011 18 24
46. J.E. East, B.P. Saunders, and J.R. Jass Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management Gastroenterol Clin North Am 37 2008 25 46 (Pubitemid 351289032)
47. H. Hampel, W.L. Frankel, and E. Martin Feasibility of screening for Lynch syndrome among patients with colorectal cancer J Clin Oncol 26 2008 5783 5788
48. H. Hampel, J.A. Stephens, and E. Pukkala Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset Gastroenterology 129 2005 415 421 (Pubitemid 41096629)
49. Classics in oncology. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Aldred Scott Warthin. 1913 CA Cancer J Clin 35 1985 348 359
50. H.T. Lynch, M.W. Shaw, and C.W. Magnuson Hereditary factors in cancer. Study of two large midwestern kindreds Arch Intern Med 117 1966 206 212
51. H.F. Vasen, J.P. Mecklin, and P.M. Khan The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) Dis Colon Rectum 34 1991 424 425
52. H.F. Vasen, P. Watson, and J.P. Mecklin New clinical criteria for hereditary nonpolyposis colorectal cancer proposed by the International Collaborative group on HNPCC Gastroenterology 116 1999 1453 1456 (Pubitemid 29258894)
53. A. Umar, C.R. Boland, and J.P. Terdiman Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 96 2004 261 268 (Pubitemid 38256271)
54. M.J. Berends, Y. Wu, and R.H. Sijmons Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant Am J Hum Genet 70 2002 26 37 (Pubitemid 34031695)
55. B.M. Buttin, M.A. Powell, and D.G. Mutch Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history Am J Hum Genet 74 2004 1262 1269 (Pubitemid 38669325)
56. V. Bonadona, B. Bonaïti, and S. Olschwang Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome JAMA 305 2011 2304 2310
57. R. Kariola, H. Hampel, and W.L. Frankel MSH6 missense mutations are often associated with no or low cancer susceptibility Br J Cancer 91 2004 1287 1292 (Pubitemid 39424789)
58. P. Peltomäki Lynch syndrome genes Fam Cancer 4 2005 227 232 (Pubitemid 41242191)
59. N.M. Lindor, K. Rabe, and G.M. Petersen Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X JAMA 293 2005 1979 1985 (Pubitemid 40570891)
60. J.M. Cunningham, E.R. Christensen, and D.J. Tester Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability Cancer Res 58 1998 3455 3460 (Pubitemid 28371090)
61. E. Capel, J.F. Fléjou, and R. Hamelin Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis Oncogene 26 2007 7596 7600 (Pubitemid 350207716)
62. M. Bettstetter, S. Dechant, and P. Ruemmele Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR Clin Cancer Res 13 2007 3221 3228 (Pubitemid 46944905)
63. M.P. Hitchins, J.J. Wong, and G. Suthers Inheritance of a cancer-associated MLH1 germ-line epimutation N Engl J Med 356 2007 697 705
64. A. McGivern, C.V. Wynter, and V.L. Whitehall Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer Fam Cancer 3 2004 101 107 (Pubitemid 40645891)
65. G. Deng, I. Bell, and S. Crawley BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer Clin Cancer Res 10 2004 191 195 (Pubitemid 38114179)
66. B. Halvarsson, A. Lindblom, and L. Johansson Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer Mod Pathol 18 2005 1095 1101 (Pubitemid 41224500)
67. F.E. Rijcken, H. Hollema, and J.H. Kleibeuker Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation Gut 50 2002 382 386 (Pubitemid 34161056)
68. M.S. Pino, M. Mino-Kenudson, and B.M. Wildemore Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas J Mol Diagn 11 2009 238 247
69. S.R. Owens, S.I. Chiosea, and S.F. Kuan Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps Mod Pathol 21 2008 660 669 (Pubitemid 351744844)
70. T.B. Sheridan, H. Fenton, and M.R. Lewin Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions caught in the act. Am J Clin Pathol 126 2006 564 571 (Pubitemid 44498506)
71. P. Galiatsatos, and W.D. Foulkes Familial adenomatous polyposis Am J Gastroenterol 101 2006 385 398 (Pubitemid 43381685)
72. M. Goodenberger, and N.M. Lindor Lynch syndrome and MYH-associated polyposis: review and testing strategy J Clin Gastroenterol 45 2011 488 500
73. L. Lipton, S.E. Halford, and V. Johnson Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway Cancer Res 63 2003 7595 7599 (Pubitemid 37466679)
74. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137 (Pubitemid 33674041)
75. R. Dienstmann, E. Vilar, and J. Tabernero Molecular predictors of response to chemotherapy in colorectal cancer Cancer J 17 2011 114 126
76. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
77. Z. Tsuchihashi, S. Khambata-Ford, and N. Hanna Responsiveness to cetuximab without mutations in EGFR N Engl J Med 353 2005 208 209 (Pubitemid 41058356)
78. T.D. Barber, B. Vogelstein, and K.W. Kinzler Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 2883 2004 351
79. B. Metzger, L. Chambeau, and D.Y. Begon The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain BMC Med Genet 12 2011 144
80. Distribution of somatic mutation in KRAS. COSMIC Database v57, release date 18Jan12, Sanger Institute. http://www.sanger.ac.uk/perl/genetics//CGP/ cosmic/. Accessed 28 Feb 12.
81. A.D. Roth, S. Tejpar, and M. Delorenzi Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
82. G. Hutchins, K. Southward, and K. Handley Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer J Clin Oncol 29 2011 1261 1270
83. H.J. Andreyev, A.R. Norman, and D. Cunningham Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 2001 692 696 (Pubitemid 32929467)
84. A. Lièvre, J.B. Bachet, and D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
85. S. Siena, A. Sartore-Bianchi, and F. Di Nicolantonio Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
86. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
87. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
88. C.J. Allegra, J.M. Jessup, and M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
89. F.A. Monzon, S. Ogino, and M.E. Hammond The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer Arch Pathol Lab Med 133 2009 1600 1606
90. T.P. Plesec, and J.L. Hunt KRAS mutation testing in colorectal cancer Adv Anat Pathol 16 2009 196 203
91. K. Balschun, J. Haag, and A.K. Wenke KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications J Mol Diagn 13 2011 436 445
92. T. Watanabe, T. Kobunai, and Y. Yamamoto Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer Dis Colon Rectum 54 2011 1170 1178
93. W. De Roock, D.J. Jonker, and F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
94. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
95. K. Fransén, M. Klintenäs, and A. Osterström Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas Carcinogenesis 25 2004 527 533 (Pubitemid 38528645)
96. Distribution of somatic mutation in BRAF. COSMIC Database v57, release date 18Jan12, Sanger Institute. http://www.sanger.ac.uk/perl/genetics//CGP/ cosmic/. Accessed 28 Feb 12.
97. J. Tol, I.D. Nagtegaal, and C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 2009 98 99
98. T. Yokota, T. Ura, and N. Shibata BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer Br J Cancer 104 2011 856 862
99. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
100. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
101. NCCN clinical practice guidelines in oncology, colon cancer. Version 2.2012.
102. J. Zhang, T.M. Roberts, and R.A. Shivdasani Targeting PI3K signaling as a therapeutic approach for colorectal cancer Gastroenterology 141 2011 50 61
103. L. Zhao, and P.K. Vogt Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS Cell Cycle 9 2010 596 600
104. F. Perrone, A. Lampis, and M. Orsenigo PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 2009 84 90
105. A. Sartore-Bianchi, M. Martini, and F. Molinari PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 2009 1851 1857
106. H. Prenen, J. De Schutter, and B. Jacobs PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer Clin Cancer Res 15 2009 3184 3188
107. C. Mao, Z.Y. Yang, and X.F. Hu PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Ann Oncol 2011 [Epub ahead of print]
108. B. Heald, J. Mester, and L. Rybicki Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers Gastroenterology 139 2010 1927 1933
109. K.S. Jang, Y.S. Song, and S.H. Jang Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma Histopathology 56 2010 229 239
110. C. Mao, R.Y. Liao, and Q. Chen Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer Br J Cancer 102 2010 940